临床病理特点 |
| 单因素 |
|
| 多因素 |
|
| HR | 95%CI | P值 | HR | 95%CI | P值 |
性别 |
|
|
|
|
|
|
男 | 1 |
|
| 1 |
|
|
女 | 1.936 | 1.164~3.220 | 0.011 | 0.723 | 0.305~1.714 | 0.462 |
年龄(岁) |
|
|
|
|
|
|
<65 | 1 |
|
| 1 |
|
|
³65 | 1.268 | 0.774~2.078 | 0.345 | 0.345 | 0.174~0.684 | 0.002 |
肿瘤分期 |
|
|
|
|
|
|
III期 | 1 |
|
| 1 |
|
|
IV期 | 2.051 | 1.221~3.444 | 0.007 | 2.436 | 1.178~5.039 | 0.016 |
靶向药物 |
|
|
|
|
|
|
埃克替尼 | 1 |
|
| 1 |
|
|
厄洛替尼 | 1 |
|
| 1 |
|
|
吉非替尼 | 1.191 | 0.843~1.684 | 0.322 | 0.652 | 0.421~1.011 | 0.652 |
中性粒细胞计数(109/L) |
|
|
|
|
|
|
<6.3 | 1 |
|
| 1 |
|
|
≥6.3 | 2.772 | 1.156~6.646 | 0.022 | 8.095 | 2.379~27.546 | 0.001 |
单核细胞计数(109/L) |
|
|
|
|
|
|
<0.6 | 0.642 | 0.335~1.231 | 0.182 | 0.304 | 0.128~0.725 | 0.007 |
≥0.6 | 1 |
|
| 1 |
|
|
纤维蛋白原(g/L) |
|
|
|
|
|
|
<3.5 | 0.877 | 0.522~1.473 | 0.621 | 0.448 | 0.236~0.849 | 0.014 |
≥3.5 | 1 |
|
| 1 |
|
|
血清白蛋白(g/L) |
|
|
|
|
|
|
<35 | 0.448 | 0.262~0.764 | 0.003 | 0.355 | 0.148~0.852 | 0.020 |
≥35 | 1 |
|
| 1 |
|
|
淋巴细胞计数(109/L) |
|
|
|
|
|
|
<1.1 | 0.395 | 0.220~0.710 | 0.002 | 0.361 | 0.172~0.756 | 0.007 |
≥1.1 | 1 |
|
| 1 |
|
|
IEF |
|
|
|
|
|
|
<1.066 × 10^17 | 1 |
|
| 1 |
|
|
³1.066 × 10^17 | 5.249 | 2.804~9.825 | <0.001 | 5.215 | 2.372~27.546 | <0.001 |